ABVC - Company ID 0001173313
ABVC BIOPHARMA, INC. trades as ABVC. In its fiscal 2025 annual report the company posted revenue of $296.00K, down 41.9% from the prior year and net income of -$7.91M. This page tracks ABVC BIOPHARMA, INC. through 780 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -87184.2% to -2671.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-18 |
| NT 10-Q | - | 2026-05-15 |
| POS AM | - | 2026-03-27 |
| Major company event | 8-K | 2026-03-27 |
| Proxy statement | DEF 14A | 2026-03-05 |
| Annual report | 10-K | 2026-03-03 |
| Quarterly report (amended) | 10-Q/A | 2026-03-03 |
| Major company event | 8-K | 2026-03-03 |
The largest companies sharing ABVC BIOPHARMA, INC.'s SEC industry classification (pharmaceutical preparations).
ABVC BIOPHARMA, INC. reported revenue of $296.00K for fiscal year 2025, a decrease of 41.9% year over year.
In its latest fiscal year ABVC BIOPHARMA, INC. reported a net loss of $7.91M.